{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:20:44Z","timestamp":1782854444946,"version":"3.54.5"},"reference-count":61,"publisher":"Royal Society of Chemistry (RSC)","issue":"17","license":[{"start":{"date-parts":[[2027,3,31]],"date-time":"2027-03-31T00:00:00Z","timestamp":1806451200000},"content-version":"am","delay-in-days":454,"URL":"http:\/\/rsc.li\/journals-terms-of-use"}],"content-domain":{"domain":["rsc.org"],"crossmark-restriction":true},"short-container-title":["Anal. Methods"],"abstract":"<jats:p>\n                    Greenness metrics, identification and quantification of\n                    <jats:italic>N<\/jats:italic>\n                    -nitroso-desformyl riociguat by UHPLC-MS\/MS, a potential carcinogenic nitrosamine drug substance-related impurity, in the vasodilatory drug riociguat, used to treat pulmonary hypertension.\n                  <\/jats:p>","DOI":"10.1039\/d6ay00279j","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:30:07Z","timestamp":1774953007000},"page":"3532-3544","update-policy":"https:\/\/doi.org\/10.1039\/rsc_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A green analytical method for identification and quantification of carcinogenic impurity\n                    <i>N<\/i>\n                    -nitroso-desformyl riociguat in riociguat formulations by UHPLC-MS\/MS"],"prefix":"10.1039","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-0250","authenticated-orcid":false,"given":"Veeraswami","family":"Boddu","sequence":"first","affiliation":[{"name":"Department of Chemistry, GITAM School of Science, GITAM Deemed to be University, Visakhapatnam, 530045, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0160-337X","authenticated-orcid":false,"given":"Manoj Kumar","family":"Mandapaka","sequence":"additional","affiliation":[{"name":"Department of Chemistry, GITAM School of Science, GITAM Deemed to be University, Visakhapatnam, 530045, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"292","published-online":{"date-parts":[[2026]]},"reference":[{"key":"D6AY00279J\/cit1\/1","author":"European Medicines Agency \u2013 EMA","year":"2019","unstructured":"European Medicines Agency \u2013 EMA ,  Angiotensin-II-Receptor Antagonists (Sartans) Containing a Tetrazole Group ,  2019"},{"key":"D6AY00279J\/cit2\/1","author":"U.S. Food and Drug Administration","unstructured":"U.S. Food and Drug Administration ,  Pharmaceutical analysis and characterization of nitrosamine impurities within angiotensin II receptor blocker drug products , Available from:  https:\/\/www.fda.gov\/media\/148748\/download"},{"key":"D6AY00279J\/cit3\/1","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration ,  FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall ,  Press Release ,  2019"},{"key":"D6AY00279J\/cit4\/1","author":"European Medicines Agency \u2013 EMA","year":"2020","unstructured":"European Medicines Agency \u2013 EMA ,  EMA Review of Impurities in Sartan Medicines EMA\/643116\/2018 ,  European Medicines Agency ,  London ,  2020"},{"issue":"42","key":"D6AY00279J\/cit5\/1","doi-asserted-by":"publisher","first-page":"23462","DOI":"10.1039\/C8RA10442F","volume":"9","author":"Allen","year":"2019","journal-title":"RSC Adv."},{"issue":"32","key":"D6AY00279J\/cit6\/1","doi-asserted-by":"publisher","first-page":"40567","DOI":"10.1039\/D0RA09530K","volume":"11","author":"Smith","year":"2021","journal-title":"RSC Adv."},{"key":"D6AY00279J\/cit7\/1","year":"2023","unstructured":"Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities Guidance for Industry , U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Pharmacology\/Toxicology,  2023"},{"key":"D6AY00279J\/cit8\/1","author":"Health Canada","year":"2024","unstructured":"Health Canada ,  Guidance on nitrosamine impurities in Medications:Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products ,  2024"},{"key":"D6AY00279J\/cit9\/1","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency ,  Nitrosamines: Information and Regulatory Updates , EMA\/409815\/2020, Rev.20,  2024"},{"issue":"21","key":"D6AY00279J\/cit10\/1","doi-asserted-by":"publisher","first-page":"21982","DOI":"10.1039\/C9RA10723A","volume":"10","author":"Thompson","year":"2020","journal-title":"RSC Adv."},{"key":"D6AY00279J\/cit11\/1","author":"ICH","year":"2023","unstructured":"ICH ,  Multidisciplinary M7 (R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk , International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human Use,  2023"},{"issue":"16","key":"D6AY00279J\/cit12\/1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1039\/D1AN01485A","volume":"14","author":"Jones","year":"2022","journal-title":"Anal. Methods"},{"issue":"3","key":"D6AY00279J\/cit13\/1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3810\/hp.2012.08.991","volume":"40","author":"Ali","year":"2012","journal-title":"Hosp. Pract."},{"issue":"12","key":"D6AY00279J\/cit14\/1","first-page":"100","volume":"11","author":"Nayak","year":"2021","journal-title":"J. Appl. Pharm. Sci."},{"key":"D6AY00279J\/cit15\/1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","volume":"31","author":"Wichitnithad","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"D6AY00279J\/cit16\/1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","volume":"27","author":"Cioc","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"D6AY00279J\/cit17\/1","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"D6AY00279J\/cit18\/1","doi-asserted-by":"publisher","first-page":"114104","DOI":"10.1016\/j.jpba.2021.114104","volume":"197","author":"White","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"12","key":"D6AY00279J\/cit19\/1","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1007\/s00216-021-03234-6","volume":"414","author":"Williams","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"key":"D6AY00279J\/cit20\/1","doi-asserted-by":"publisher","DOI":"10.1002\/0471435139.tox055","volume-title":"Patty's Toxicology","author":"Lijinsky","year":"2001","unstructured":"W.Lijinsky ,  N-Nitroso Compounds , in  Patty's Toxicology , ed.  E. Bingham ,  B. Cohrssen  and  C. H. Powell ,  2001 ,  10.1002\/0471435139.tox055"},{"key":"D6AY00279J\/cit21\/1","doi-asserted-by":"publisher","DOI":"10.1002\/0471435139.tox055.pub2","volume-title":"Patty's Toxicology","author":"Clapp","year":"2012","unstructured":"R.Clapp ,  M.Jacobs  and  W.Lijinsky ,  N-Nitroso Compounds , in  Patty's Toxicology , ed.  E. Bingham ,  B. Cohrssen  and  C. H. Powell ,  2012 ,  10.1002\/0471435139.tox055.pub2"},{"key":"D6AY00279J\/cit22\/1","author":"Therapeutic Goods Administration (TGA), Australian Government","year":"2025","unstructured":"Therapeutic Goods Administration (TGA), Australian Government ,  Established acceptable intake for nitrosamines in medicines ,  2025"},{"issue":"4","key":"D6AY00279J\/cit23\/1","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1021\/acs.analchem.9b05687","volume":"92","author":"Chen","year":"2020","journal-title":"Anal. Chem."},{"issue":"3","key":"D6AY00279J\/cit24\/1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1039\/D0RA09530K","volume":"11","author":"Brown","year":"2021","journal-title":"RSC Adv."},{"key":"D6AY00279J\/cit25\/1","author":"U.S. Food and Drug Administration \u2013 FDA","year":"2019","unstructured":"U.S. Food and Drug Administration \u2013 FDA ,  Liquid Chromatography-High Resolution Mass Spectrometry (LCHRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs ,  2019"},{"key":"D6AY00279J\/cit26\/1","author":"U.S. Food and Drug Administration \u2013 FDA","year":"2020","unstructured":"U.S. Food and Drug Administration \u2013 FDA ,  Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product ,  2020"},{"issue":"8","key":"D6AY00279J\/cit27\/1","doi-asserted-by":"publisher","first-page":"8773","DOI":"10.1021\/acsomega.3c05170","volume":"9","author":"Nakka","year":"2024","journal-title":"ACS Omega"},{"issue":"18","key":"D6AY00279J\/cit28\/1","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1039\/C9AN02418A","volume":"12","author":"Green","year":"2020","journal-title":"Anal. Methods"},{"issue":"4","key":"D6AY00279J\/cit29\/1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/acs.jchemed.9b00389","volume":"96","author":"Harris","year":"2019","journal-title":"J. Chem. Educ."},{"issue":"22","key":"D6AY00279J\/cit30\/1","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1039\/D2AY01148B","volume":"14","author":"Clark","year":"2022","journal-title":"Anal. Methods"},{"key":"D6AY00279J\/cit31\/1","volume-title":"AN 73814, HRAM LC-MS Method for the Determination of Nitrosamine Impurities in Drugs","author":"Yang","year":"2020","unstructured":"H.Yang ,  J.Bardsley ,  M.Du  and  O.Scheibner ,  AN 73814, HRAM LC-MS Method for the Determination of Nitrosamine Impurities in Drugs ,  ThermoFisher Scientific ,  2020 , [accessed May 2024]"},{"key":"D6AY00279J\/cit32\/1","author":"Du","unstructured":"W.Du  and  X.Ran ,  Determination of 8 Nitrosamines in Water by Liquid Chromatography Coupled to Tandem Mass Spectrometry ,  Agilent Technologies (China) Co. Ltd ,  Beijing, China , Available from: https:\/\/lcms.labrulez.com\/labrulezbucketstrapih3hsga3\/Agilent_ASMS_2019_TP_188_Poster_a7535330cf\/Agilent_ASMS_2019_TP188_Poster.pdf , accessed May 2024"},{"issue":"6","key":"D6AY00279J\/cit33\/1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/22297928.2024.2417185","volume":"14","author":"Mandapaka","year":"2024","journal-title":"Anal. Chem. Lett."},{"key":"D6AY00279J\/cit34\/1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1039\/D4AY01710B","volume":"17","author":"Yadav","year":"2025","journal-title":"Anal. Methods"},{"issue":"5","key":"D6AY00279J\/cit35\/1","doi-asserted-by":"publisher","first-page":"e70065","DOI":"10.1002\/sscp.70065","volume":"8","author":"Mandapaka","year":"2025","journal-title":"Sep. Sci. Plus"},{"key":"D6AY00279J\/cit36\/1","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.scp.2024.101495","volume":"38","author":"Nakka","year":"2024","journal-title":"Sustainable Chem. Pharm."},{"key":"D6AY00279J\/cit37\/1","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1039\/D4RA08425J","volume":"15","author":"Nakka","year":"2025","journal-title":"RSC Adv."},{"key":"D6AY00279J\/cit38\/1","author":"ICH","year":"2024","unstructured":"ICH ,  Quality Q2 (R2): Validation of Analytical Procedures. Center for Drug Evaluation and Research (CDER) ,  Food and Drug Administration ,  2024"},{"key":"D6AY00279J\/cit39\/1","author":"ICH","year":"2023","unstructured":"ICH ,  Quality Q14: Analytical Procedure Development , International Council for Harmonisation of Technical Requirements for Pharmaceutical for Human Use,  2023"},{"key":"D6AY00279J\/cit40\/1","author":"ISO14001:2015 International Organization for Standardization","year":"2015","unstructured":"ISO14001:2015 International Organization for Standardization ,  Environmental management systems-Requirements with guidance for use ,  2015"},{"key":"D6AY00279J\/cit41\/1","author":"Synthink Chemicals Ltd","year":"2025","unstructured":"Synthink Chemicals Ltd ,  Riociguat N-Nitroso Des Formyl Impurity Product Data , accessed  2025"},{"key":"D6AY00279J\/cit42\/1","author":"Diacel Pharma Standards","year":"2025","unstructured":"Diacel Pharma Standards ,  NDSRI's, Riociguat, Riociguat Nitroso Impurity-1 , accessed  2025"},{"key":"D6AY00279J\/cit43\/1","author":"Simson Pharma","year":"2025","unstructured":"Simson Pharma ,  Riociguat N-Nitroso Des Formyl Impurity Product Data , accessed  2025"},{"key":"D6AY00279J\/cit44\/1","doi-asserted-by":"crossref","first-page":"122532","DOI":"10.1016\/j.talanta.2021.122532","volume":"233","author":"P\u0142otka-Wasylka","year":"2021","journal-title":"Talanta"},{"key":"D6AY00279J\/cit45\/1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"P\u0142otka-Wasylka","year":"2018","journal-title":"Talanta"},{"issue":"1","key":"D6AY00279J\/cit46\/1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00216-022-04337-z","volume":"415","author":"Nowak","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"D6AY00279J\/cit47\/1","doi-asserted-by":"publisher","first-page":"106314","DOI":"10.1016\/j.microc.2021.106314","volume":"167","author":"Dinc","year":"2021","journal-title":"Microchem. J."},{"key":"D6AY00279J\/cit48\/1","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency ,  Nitrosamines: Information and Regulatory Updates , EMA\/409815\/2020, Rev.20,  2024"},{"key":"D6AY00279J\/cit49\/1","author":"U.S. Food and Drug Administration","year":"2021","unstructured":"U.S. Food and Drug Administration ,  Control of Nitrosamine Impurities in Human Drugs ,  Center for Drug Evaluation and Research (CDER) ,  2021"},{"key":"D6AY00279J\/cit50\/1","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)\/The National Health Surveillance Agency-Brazil","year":"2023","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)\/The National Health Surveillance Agency-Brazil ,  Guide on Nitrosamine Control ,  2023"},{"key":"D6AY00279J\/cit51\/1","author":"Health Canada","year":"2024","unstructured":"Health Canada ,  Guidance on nitrosamine impurities in medications ,  2024"},{"key":"D6AY00279J\/cit52\/1","unstructured":"USP &lt;1225&gt;: United States Pharmacopeial Convention (USP) general chapter titled, \u201cValidation of Compendial Procedures\u201d"},{"key":"D6AY00279J\/cit53\/1","unstructured":"USP &lt;1469&gt;: United States Pharmacopeial Convention (USP) general chapter titled \u201cNitrosamine Impurities\u201d"},{"key":"D6AY00279J\/cit54\/1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"Ga\u0142uszka","year":"2022","journal-title":"TrAC, Trends Anal. Chem."},{"key":"D6AY00279J\/cit55\/1","first-page":"115112","volume":"224","author":"Chen","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"D6AY00279J\/cit56\/1","volume-title":"Green Analytical Chemistry: Past, Present, and Future","author":"P\u0142otka-Wasylka","year":"2022","unstructured":"J.P\u0142otka-Wasylka  and  J.Namie\u015bnik ,  Green Analytical Chemistry: Past, Present, and Future ,  Springer ,  Cham ,  2022"},{"key":"D6AY00279J\/cit57\/1","first-page":"463623","volume":"1689","author":"Lopez-Avila","year":"2023","journal-title":"J. Chromatogr. A"},{"key":"D6AY00279J\/cit58\/1","first-page":"108098","volume":"184","author":"Nowak","year":"2023","journal-title":"Microchem. J."},{"key":"D6AY00279J\/cit59\/1","first-page":"116933","author":"Ga\u0142uszka","year":"2023","journal-title":"TrAC, Trends Anal. Chem."},{"key":"D6AY00279J\/cit60\/1","doi-asserted-by":"crossref","first-page":"137756","DOI":"10.1016\/j.chemosphere.2023.137756","volume":"315","author":"Pena-Pereira","year":"2023","journal-title":"Chemosphere"},{"key":"D6AY00279J\/cit61\/1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1039\/D3GC04048H","volume":"26","author":"P\u0142otka-Wasylka","year":"2024","journal-title":"Green Chem."}],"container-title":["Analytical Methods"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.rsc.org\/en\/content\/articlepdf\/2026\/AY\/D6AY00279J","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:23:13Z","timestamp":1782850993000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.rsc.org\/ay\/article\/18\/17\/3532-3544\/1237541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":61,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1039\/d6ay00279j","relation":{},"ISSN":["1759-9660","1759-9679"],"issn-type":[{"value":"1759-9660","type":"print"},{"value":"1759-9679","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}